DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials in their products for pharmaceutical and medical devices under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's advanced oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including REMOXY ER, an investigational extended release pain relief drug based on ORADUR technology; and POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has collaboration agreements with Sandoz AG; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Zogenix, Inc.; and Pain Therapeutics, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DRRX
CUSIPN/A
Phone408-777-1417
Debt
Debt-to-Equity Ratio0.50
Current Ratio4.61
Quick Ratio4.32
Price-To-Earnings
Trailing P/E Ratio-68.33
Forward P/E Ratio-8.91
P/E GrowthN/A
Sales & Book Value
Annual Sales$49.17 million
Price / Sales6.74
Cash FlowN/A
Price / CashN/A
Book Value$0.14 per share
Price / Book14.64
Profitability
EPS (Most Recent Fiscal Year)($0.03)
Net Income$-3,690,000.00
Net Margins-8.06%
Return on Equity-25.82%
Return on Assets-7.04%
Miscellaneous
Employees93
Outstanding Shares161,710,000
DURECT (NASDAQ:DRRX) Frequently Asked Questions
What is DURECT's stock symbol?
DURECT trades on the NASDAQ under the ticker symbol "DRRX."
How were DURECT's earnings last quarter?
DURECT Co. (NASDAQ:DRRX) issued its earnings results on Wednesday, May, 2nd. The specialty pharmaceutical company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. The specialty pharmaceutical company had revenue of $3.49 million for the quarter, compared to analyst estimates of $4.20 million. DURECT had a negative return on equity of 25.82% and a negative net margin of 8.06%. View DURECT's Earnings History.
When is DURECT's next earnings date?
What price target have analysts set for DRRX?
3 equities research analysts have issued 1-year price targets for DURECT's shares. Their predictions range from $2.00 to $3.50. On average, they anticipate DURECT's stock price to reach $2.8333 in the next twelve months. View Analyst Ratings for DURECT.
Who are some of DURECT's key competitors?
Some companies that are related to DURECT include Apellis Pharmaceuticals (APLS), Impax Laboratories (IPXL), Theravance Biopharma (TBPH), IMMURON Ltd/S (IMRN), Arrowhead Pharmaceuticals (ARWR), Alder Biopharmaceuticals (ALDR), Zai Lab (ZLAB), Athenex (ATNX), Revance Therapeutics (RVNC), Retrophin (RTRX), Eagle Pharmaceuticals (EGRX), Intra-Cellular Therapies (ITCI), Esperion Therapeutics (ESPR), TG Therapeutics Inc common stock (TGTX) and Reata Pharmaceuticals (RETA).
Who are DURECT's key executives?
DURECT's management team includes the folowing people:
- Dr. Felix Theeuwes, Co-Founder, Chairman & Distinguished Scientist (Age 80)
- Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 61)
- Mr. Matthew J. Hogan, CFO & Sec. (Age 58)
- Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 61)
- Mr. Michael H. Arenberg J.D., M.B.A., Sr. VP of Corp. & Bus. Devel.
Has DURECT been receiving favorable news coverage?
Media headlines about DRRX stock have trended somewhat positive this week, according to Accern. Accern identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. DURECT earned a news sentiment score of 0.08 on Accern's scale. They also assigned news stories about the specialty pharmaceutical company an impact score of 45.42 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are DURECT's major shareholders?
DURECT's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.10%), Northern Trust Corp (1.00%), Asymmetry Capital Management L.P. (0.47%), Millennium Management LLC (0.42%), Algert Global LLC (0.31%) and Mackay Shields LLC (0.11%). View Institutional Ownership Trends for DURECT.
Which institutional investors are selling DURECT stock?
Which institutional investors are buying DURECT stock?
DRRX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Algert Global LLC, Mackay Shields LLC, Engineers Gate Manager LP, MetLife Investment Advisors LLC, Cubist Systematic Strategies LLC and Northern Trust Corp. View Insider Buying and Selling for DURECT.
How do I buy shares of DURECT?
Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DURECT's stock price today?
One share of DRRX stock can currently be purchased for approximately $2.05.
How big of a company is DURECT?
DURECT has a market capitalization of $339.59 million and generates $49.17 million in revenue each year. The specialty pharmaceutical company earns $-3,690,000.00 in net income (profit) each year or ($0.03) on an earnings per share basis. DURECT employs 93 workers across the globe.
How can I contact DURECT?
DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.
MarketBeat Community Rating for DURECT (DRRX)
MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote "Outperform" if you believe DRRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
